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Abstract 
Drug resistance is one of the major causes for HIV-infected patients to lose lives. An innovative and 
potent HIV-1 protease inhibitor scaffold needs to be developed to resolve drug resistance issues. During 
this investigation, HIV-1 protease inhibitors based on a novel keto-hydroxyethylene core were designed 
and synthesized based on the substrate envelope theory. This core targets to overcome drug resistance to 
Amprenavir and Darunavir caused by I50V mutation in protease. The results of florescence resonance 
energy transfer (FRET) assays indicate that the new inhibitor has moderate enzymatic inhibitory activities 
against HIV-1 protease. In the future, a variety of drug analogues will be developed based on this new 
core structure and might provide better therapies against drug-resistant HIV-1.  
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Introduction  
Acquired immune deficiency syndrome (AIDS)  
AIDS was statically ranked fifth as the cause of death for people from age 25 to 44 in the United States.  
According to United Nation Program on AIDS/HIV (UNAIDS) reports, 33.3 million people in the world 
are infected with HIV. Among those populations, 2.5 million are children. In the year of 2009, the number 
of infected patients increased by 2.6 million, and approximately 1.8 million people died from AIDS. HIV 
virus destroys the immune system by killing “CD4+ T cells” and causes the body to become vulnerable to 
even benign bacterial infections and other diseases. At the moment there is no complete cure for HIV-
infected patients.  However, antiviral drugs are capable of suppressing the proliferation of the HIV and 
relieving the symptoms of AIDS. Patients who have AIDS display following symptoms: suffer from 
gastrointestinal system failure, from no appetite to acute diarrhea; respiratory system failure ranges from 
shortness of breath to intensive coughs; skin rash and lesions, for instance, infected with fungi or bacteria, 
neurological system failure, markedly numbness, burning, confusion, and loss of consciousness. Virus 
seriously destroys the health of patients, spreads at an uncontrollable rate and mutates as it spreads, 
increasing the challenge for developing effective medical therapies. Therefore, the developments of de 
novo drug therapies against drug resistance have been a major interest for scientists.  
Human Immunodeficiency Virus  
In order to find the therapy to control HIV replication and propose solution to this urgent problem, it is 
very necessary to have a deep understanding of the retrovirus and its replication mechanisms. HIV 
belongs to lentivirus family, identified as the descendant of the Simian Immunodeficiency virus. HIV-1 is 
the most virulent and pandemic strain; therefore, it has become the focus of study. HIV originates from 
chimpanzees and crossed species to infect humans. (Bailes, 2003)  
HIV is a type of single-stranded RNA retroviruse. It consists of multiple layers to conserve its essential 
inheriting molecules: reverse transcriptase, integrase, and protease and RNA. The outermost layer is a 
combination of glycoprotein, gp120 and gp41, forming a structure which possesses strong affinity to the 
CD4 receptors on the CD4+T lymphocytes, macrophages, microglial, dendritic and Langerhans cells. The 
co-receptor CCR-5 and CXCR4 induce conformational changes of gp120 to release from transmembrane 
protein, gp41, with an exposed cryptic epitope that causes the union of the virus cell membrane and host 
cell membrane. Especially, the two main regions of N terminus of the gp41 and the gp120 V3 loop have 
high affinity to the host cell receptors. (QJ, 1992 ) The cooperation of the co-receptor CCR-5 and CXCR4 
with CD4 enhances viral absorption and infectivity. (Kozak SL, 1997)After fusion, a pore forms at the 
attachment site which allows the viral capsid to invade the host cells. The secondary layer is the 
membrane used to bud outwardly during the viral replication. The third layer is a protein capsule, 
composed of p-17 on the outside and a p-24 layer in the center. Inside of the core, which is enclosed by 
p24, all the essential enzymes and RNA are safely protected.  
 
Figure 1 HIV virus molecular structure. (Freed, 1998) 
With the escort of co-receptors, HIV virus easily recognizes the door to enter the host cells. It binds to the 
receptor on the host cells and then the p-24 capsule unpacks its package to release viral RNA and other 
genomic molecules to the host cell cytoplasm.  HIV Reverse transcriptase works as a reverse translator, 
converting the genetic information form viral RNA to the viral DNA strand, followed by the action of 
integrase which works as a scissor to cut the host DNA strand, as glue to connect viral DNA to the host 
genome. Once they are connected, RNA polymerase from host cells works to transcript DNA into mRNA, 
which flows into the cytoplasm from the host cell nuclear pore and directs the expression of viral protein. 
p-160 and p-55 are assembled at the smooth ribosome and aggregate on the cell inner surface of the host 
cell membrane. gp160 is processed in the endoplasmic reticulum, and dissembles into gp120 and gp41, 
which integrates with the host cell membrane as well. The replicated viral protein and RNA eventually 
buds out of the host cells. Meanwhile,  HIV replication reaches its final stage where protease cleaves the 
proteins p160 and p55 and form p17 and p24 respectively. (Freed, 1998) 
 
Figure2. HIV replication life cycle (Snyder, 2004) 
HIV-1 virus is composed of three major proteins, Gag, Pol, and Env, as shown in figure3. Among those 
components, Gag acts as the leader.  At the initial stage of the virus formation, it becomes the major body 
component of most viral-like noninfectious particles.  Later on, it undergoes a morphological transition; 
the maturation of the virus forms an infectious characteristic of central cone-shaped structure. The 
maturation is caused by a dramatic conformational change of Gag protein. Gag protein carries out  
multiple tasks, it folds for assemblies and creates multimeric structure to facilitate the assessment to the 
plasma membrane. Meanwhile, it allows virus to invade the cells and carries out the dissembling process 
to expose the core. Env encodes protein consisting of the surfaces and viral envelop. Without the envelop 
protein gp120, HIV cannot navigate to the CD4 receptor and cling to the right location. Without Env 
trans-membrane gp41 function, HIV virus cannot fuse into the host cells. Protease cleaves the gag-pol 
precedent into gag and pol. Pol is simply the precursor of three enzymes, protease (PR), retrotranscriptase 
(RT) and intergrase (IN).  
 
Figure 3. HIV virus genome and its encoded proteins:matrix (MA)capsid (CA) nucleocapsid (NC)protease 
(PR)Retrotranscriptase (RT)Intergrase( IN)Surface protein (Su) Trans-membrane protein (™) (Freed, 1998) 
Controlling HIV-AIDS using multiple approaches  
As shown in figure2, there are seven steps of HIV replication, and the prevention of any of those steps 
during HIV propagation will significantly destroy the viral life cycle and cease the AIDS development. 
Current drugs are based on the idea of blocking the HIV life cycle’s crucial steps. There are five types of 
major HIV antiviral drugs, nucleoside RT Inhibitors (NRTIs), non-nucleoside RT inhibitors (NNRTIs), 
protease inhibitors (PIs), fusion inhibitors (FIs), and integrase inhibitors (INIs).  
Table 1. Clinical HIV antiviral drugs. The listed names are the common name used in pharmacy. 
 
The first class of HIV drug, approved in 1987 by FDA, isNRTIs.  The philosophy of the drug design is to 
synthesize a molecule which blocks the elongation process of RNA or DNA chains during HIV 
replication. This is achieved by replacing the hydroxyl (-OH) group at 3’ position by other functional 
groups, which is not able to form the essential 5’ to 3’phosphodiester bond. As a result, NRIT’s inhibitors 
compete to bind to the substrate and act as the terminators on the nucleotide chain. In order to ensure the 
inhibitors have high affinity to compete for binding, they are intracellularly phosphorylated to their active 
5’ triphosphate forms. (David Warnke, 2007) However, this type of drug requires host cell kinase to be 
active. Kinase converts the monophosphate to triphosphate. Therefore, they are not as bioactive as other 
drugs.  
NNRTIs are usually non-competitive inhibitors since they do not directly bind to the active site, therefore, 
they do not need to be phosphorylated. However, they bind to the residues that are far from the active 
sites and induce conformational changes of reverse transcriptase enzyme and indirectly reduce the 
catalytic sites’ binding affinity. (David Warnke, 2007) 
nucleoside RT Inhibitors non-nucleoside RT inhibitors  protease inhibitors (PIs) fusion inhibitors integrase inhibitors 
Combivir Intelence Agenerase Fuzeon Isentress 
Emtriva Rescriptor Aptivus Selzentry GSK-572
Epivir Sustiva Crixivan Vicriviroc Elvitegravir 
Epzicom Viramune Invirase Ibalizumab 
Retrovir Rilpivirine Kaletra PRO 140 
Trizivir Lexiva
Truvada Norvir
Videx Prezista
Viread Reyataz
Zerit Viracept
Ziagen
Racivir (RCV)
Amdoxovir
Apricitabine
Elvucitabine
Fusion Inhibitors are designed to interrupt the stage of HIV life cycle where viral glycoprotein attaches to 
the host cellular receptors. (David Warnke, 2007) Intergrase inhibitors are designed to block the action of 
viral intergrase, and as a result, the viral DNA cannot incorporate into the host DNA, and therefore, viral 
protein cannot be expressed. Other types of drugs are designed to block different steps of this stage of 
viral replication, such as blocking the function of transcription factors, activators, promoters or regulators. 
Protease inhibitors are designed to prevent HIV protease from binding to the substrate; as a result, HIV 
protease cannot cleave gag-pol, and generate mature and active protein.  
Comparing to all other inhibitors, PIs have become the focus of study nowadays because of its high 
efficacy and minimal side effects.  Before the PIs can be developed, the study of biochemical reaction of 
HIV-1 protease is important for scientists to find solution to invent effective inhibitors.  
HIV Protease  
In general, viral proteases have been observed to cleave the gigantic protein precursor and produce active 
but smaller sized functional proteins. The catalytic mechanism belongs to the well-known scissile bond 
interactions. Drug designs usually utilize the viral protease mechanics and kinetics feature to build up a 
simulation models by docking and computation methods. The electrostatic interactions, the forces of inter 
and intra molecular strengths and bond distances, hydrophobic interactions, thermodynamics are all 
investigated during the modeling process so that a well designed protease inhibitor structure can be 
predicted and made in silico. Afterwards, extensive chemical compounds designed from the simulations 
are synthesized and screened by biochemical assays. Then the enzymatic inhibition constant (Ki) can be 
evaluated and compared. As a result the most potent protease inhibitor can be selected to test for its 
pharmacokinetics and toxicity properties, and clinical trials are conducted before FDA approves the drugs.  
(Jeffrey Anderson, 2009) 
 
Structure of HIV protease  
HIV-I protease has become the most canonical model for study of viral protease and the precedent of 
many other drug designs, such as HCV. From the introduction of HIV replication cycle, it is known that 
Pro in the middle of Gag gene and Pol gene, Pro gene encodes a large protein procurer consists of viral 
polymerase and integrase as well as protease. Protein encoded by Gag-Pro-Pol first dimerizes to ensure 
that the protease leave the polyprotein and become active. X-ray structure reveals that HIV protease is a 
homodimeric aspartyl protease with active sites located at the dimer integration regions. (Spinelli S, 1991) 
Each monomer consists of 99 amino acid residues. Each one starts with amino acid Pro at the N-terminus 
and ends with a Phe at C -terminus.  Because its active sites contain the symmetric sequences, Asp-Thr-
Gly, it is also known as aspartyl protease, shown in figure 4.  The two motifs converge and form a tunnel 
in the middle. This tunnel is of critical importance because the active site of the protease is located in its 
interior. Those Asp-25, Asp25’ on each monomer are two of the most important active sites which 
undergo a hydrolysis reaction of the protein precursors that binds to the interfaces. One of the residues has 
a low pKa of 3.3 and the other has pKa of 5.3. All of the active sites of HIV protease are indicated in 
panel B of figure4. The hydrolysis reaction belongs to one of the fundamental reactions, an acid-based 
catalytic reaction with the presence of a water molecule. (Spinelli S, 1991)The dynamic top and flanking 
sites form anti-parallel beta sheets; this structure is known as the mobile flap, indicated in figure 4, panel 
A. During the enzymatic reaction, those mobile flaps loosen up and allow the substrate to approach active 
sites. After the substrate undergo as the hydrolysis reaction, those flaps will move and release the 
products.  Km of HIV-1 protease is 115uM and the Kcat is 12.2s
1 
and the catalytic efficacy is 106nM
-1
S
-1
. 
(Markland, 2000 ). The enzyme kinetics data suggests that HIV-1 protease has relative effective 
enzymatic activity. This characteristic of HIV protease also explains the fast replication of HIV virus. 
One point which is worthy to emphasize is that, during the enzymatic mechanism, a transient tetrahedral 
intermediate is commonly used as a model for designing of HIV protease drug inhibitors. (Jeffrey 
Anderson, 2009) 
 Figure 4. Panel A illustrates HIV protease, The residues 46-65 are labeled on those two symmetric mobile flaps that can catch 
and release the substrate.  Panel B shows the HIV protease active sites in the middle of the tunnel.The labeled residues are 
25,26,27, 29, 30, and 87.  
HIV protease cleavage sites 
HIV protease cleaves Gag-Pro-Pol proteins precursor at ten sites. Each substrate peptide sequence is 
composed of different amino acids residues, and little similarity in structures can be observed. Therefore, 
the adaptation of the substrate to protease’s shape is most likely following the “ induce fit” mechanism. 
Most of the substrates contain a residue at P2 site, hydrophobic residues at P1 site, and an aromatic or 
proline at P1’ site. (Jeffrey Anderson, 2009). Table2 shows the sequences of those ten substrates.  
Table 2. HIV protease substrate cleavage sites. 
Substrate Sites within the Gag polyprotein Substrate Sites within the Pol Polyprotein 
SQNY*PIVQ matrix-capsid RLAF*LQGK nucleocapsid*-p6Pol 
ARVL*AEAM  capsid-p2 SFNF*PQIT p6Pol-protease 
ATIM*MQRG p2-nucleocapsid QITL*WQRP auto proteolysis site 
RQAN*FLGK nucleocapsid-p1 TLNF*PISP protease-rev.trans. 
PGNF*LQSR p1-p6Gag AETF*YVDG rev.trans.-RNaseH 
 RKIL*FLDG RNaseH-integrase 
HIV protease as a therapeutic target 
HIV protease is the first drug which is used for structure based drug design. The database of antiviral 
interaction reported that NRTI causes lactic acidosis, hepatic steatosis, and lipodystrophy. Also NNRITs 
have a possibility of counteracting other drug agents, and a possibility of causing Stevens-Johnson 
syndrome, and toxic epidermal necrolysis. (Ian McNicholl, 2010 ) PIs are designed with chemical 
scaffolds that would preserve the same contacts with the protease but have superior pharmacokinetics and 
bioavailability. The majority of those drugs are peptidomimetics. Most of the protease inhibitors are 
designed with higher hydrophobicity.  The reason is that the hydrophobic cyclical side chain at PI and 
fairly protruding functional group become acceptable into the P2-P2’ region of the active site.Most of the 
approved drugs have  non-cleavable dipeptide isosteres as main scaffolds to simulate the enzymatic 
intermediate transition stage without a real cleavage. This design allows them to have better affinity and 
stronger strengths to inhibit enzyme activities.  (Jeffrey Anderson, 2009) For instance, Saquinavir was 
designed based on the structure mimics and has become the first clinical protease inhibitor to treat HIV, 
which intensely interacts with the catalytic sites Asp residues. (Tie Y, 2007) Inhibitors are usually smaller 
in size but still remain bioactive. Those features of HIV protease inhibitor easily fit and bind to protease 
active sites. Among all categories of enzyme inhibitors, HIV protease inhibitor has become the structure 
based  successful design models, and have quickly had  nine drugs approved: indinavir(IDV), nelfinavir 
(NFV), amprenavir ( APV), saquinavir(SQV), ritonavir(NFV), lopinavir(LPV), atazanavir(ATV), 
tipranavir(TPV), and darunavir(DRV).  (A.Schiffer, 2008)   
Drug resistance in HIV-1 protease  
HIV protease inhibitors are highly potent, however, just like other antiviral drug; they encounter the 
challenge of drug resistance. Drug resistance is a common issue during clinical treatments. Resistances 
cause the medicine to reduce or even lose function, and jeopardize patients’ lives. There are two types of 
drug resistance: primary resistance and induced resistance. The former refers to some strains of HIV 
naturally resistant to some antiretroviral drugs. For instance, HIV-2 strain is resistant to all of the NNRTIs. 
The latter refers to the case where  under treatment of one or more antiviral drugs, because of the 
Darwinian selection process, will naturally lead  to HIV protease mutants that can maintain viral 
replication at a relatively steady rate rather than to select the wild type protease, which is inhibited by the 
drugs. In general, the mutation of the enzyme active sites, or on the allosteric sites, cause enzyme 
conformational change, which lead to loss of binding to the enzyme, causing the inhibitor to lose its 
affinity. 
Resistance to protease inhibitors builds when single or multiple residues, either on the active sites or on a 
remote position from catalytic sites on HIV protease, convert to other residues which have different 
bonding interactions with the protease inhibitor, and as a result, inhibitors lose affinity to the protease. 
Resistance mutations in protease are usually due to the excessive inhibitors interactions to the active sites. 
The large amount of contact with active site induces protease mutation. (Clavel, 2004) Mutations at active 
sites D30N, G48V, V82A, I84V, I50V and I50L, or mutations at non-mutation sites such that V82A, and 
I84V changes the entire enzyme, make all the inhibitor lose affinity. The mutation sites other than active 
sites are L10I, I54V, T, A71V or T, V771 and L90M. (King, 2004) Mutations at non-active sites are more 
challenging than others because they not only adapt to the variation on the active sites but also adapt to 
optimize of the viability of the protease and improve on virus replication rate.  The I90M is one of the 
frequent resistance mutations selected for saquinavir therapy. The V82A, V82T and V82F can happen at 
the early stage of protease inhibitor therapy. D30N is usually chosen for nelfinavir therapy. Mutants such 
as L10I, L10F, K20R, K20M, M361, M461, M46L, I54V, I54L, A71V, A71T, G73S, V77I and M93L 
could accumulate and cause increase resistance. (Clavel, 2004) 
 
 
 
 Figure 5. HIV protease drug resistances pattern.  The labeled amine acids are active sites with mutations. 
Different approaches to design HIV protease inhibitors design 
Scientists have tried to overcome the drug resistance issues and develop innovative drug design methods 
to satisfy the need of having less toxic and more effective drugs. Some of the drugs are based on the 
Substrate envelope model, which will be explained in detail in the following section.  However, because 
of its peptide properties, higher therapeutic dose is required and a high cost of investment for drug 
synthesis is usually the case. Therefore, Ghosh and Dawson approached to develop drug candidate by 
eliminating the peptidic character. In this way, the synthesized drugs are in small size, less complex in 
form. The idea comes from a structural based natural compound which exhibits better bioavailability than 
peptides. Based on this idea, DRV, a potent drug which has strong binding affinity to both the wild type 
and mutant protease was developed based on the concept of the natural product being a form of non-
peptide compounds. (Arun K. Ghosh, 2007). The bis-THF group was used to optimize ligand binding site 
interactions, such as hydrophobic, electrostatic, and hydrogen bonding interaction at P2 position. .  
 
Substrate envelope (SE) based PI designs  
Because HIV is a single stranded retrovirus, during the viral replication genetic information is inherited 
with low fidelity due to the inaccurate transcription by RT. The high mutation rate of HIV causes medical 
issues and drug resistance.  It has become the major cause of therapeutic failure. If one of the essential 
drug-resistant mutations occurs, the resulting mutation will continue to occur in order to improve the 
protease function.  (A.Schiffer, 2008) As a result, a method which can overcome the evolutionary power 
of nature, and generate drug therapies to treat a family of the mutant enzyme, or even can adapt to the 
constant alternation of the structure is required.  According to the nature of HIV virus, no matter how the 
virus protease mutates, it will have to function to cleave the Gag and Gag-Pol gene product at a sustaining 
rate.  
One ingenious idea proposes that if the HIV protease inhibitors are designed to resemble the form of the 
substrate and its interaction patterns with protease, then HIV inhibitors compete against the actual 
substrate, and bind to the protease strongly, at the same time avoiding drug resistant mutations from 
occurring. If inhibitor interacts with protease at the same sites as the substrate, and the mutant grows 
resistance against inhibitor binding, then the mutation will cause protease to lose substrate binding as well. 
However, this condition will not be favorable to the virus according to the natural selection. Therefore, 
that inhibitor should have stronger affinity to overcome the drug resistance problem.  (Srypriya 
Chellappan Visvaldas Kairys, 2007) Crystallographic studies and other experimental observation 
suggested that the substrate of HIV protease occupies a conserved region within the binding sites despite 
the fact that they are composed of different amino acid sequences. (A.Schiffer, 2008) This consensus 
volume is called the substrate envelope, which is also known as the substrate recognition motif. Based on 
these investigations, it is hypothesized that if the inhibitor fits into this region, and does not protrude 
outside, then it can potentially overcome the drug resistances of the HIV virus. This prediction has been 
confirmed by retrospective data analysis. (Srypriya Chellappan Visvaldas Kairys, 2007).  
 
 Figure 6.  Illustration of the substrate envelope hypothesis. (Ali, 2008). Panel A shows the inhibitor and substrate binding to the 
wild type protease, panel B shows that the some inhibitor and substrate at with mutant protease. And the star labels the mutation 
sites. If the inhibitor is designed to have the same interaction with the protease as the substrate, then no matter how the influences 
given by the mutation residue, it will not changes enzymatic inhibiting constant. 
Biological Evaluation of PI Drugs 
Fluorescent Resonances Energy Transfer (FRET) Assays   
Fluorescence resonance energy transfer (FRET) measures the excited state of energy transfer from the 
initial excited donor (D) to the acceptor (A).  It is widely useful in biochemistry, since the energy transfer 
is independent of the jointer liner between D and A, but is dependent on the distance between them. It is 
used to measure the distances between two sites on a macromolecule, and is used to study molecular 
systems in which a single D-A distance is not present. Such as assemblies of proteins and membranes or 
unfolded proteins where there is a distribution of D-A distances. It is also used to measure a 
conformational change which moves the domains closer or further apart. For the HIV protease inhibitor 
study, it is used to measure the enzymatic inhibitory constant (Ki) to determine the newly synthesized 
compound’s bioactivities. The substrate is derived from natural cleavage sites of HIV PR. Also both the 
starting and ending residue, the ENDAS and the DSBCYL,  will be quenched before the substrate is 
cleaved. If the protease cleaves the substrate at Tyr and Pro, then the two molecules become no longer 
quenched but will be fluorescent because of the energy transfers. The reasons that FRET can quantify the 
amount of protease hydrolysis activity and function as a proximity indicator, relate to the time-dependent 
increase of fluorescent intensity is directly proportional to the number of substrate cleaved.  
 
Figure7. The application theory behind fluorescent resonance energy transfer assay.  
The goal of this project 
While designing new inhibitor, several principles are followed: to keep most of the functional groups 
targeted at the position of the active sites of the protease, to reduce the protruding functional groups out of 
the substrate envelope, and to maintain the compound’s size and bioavailability. It is concluded that 
because most of the drug-resistant mutation sites occurred out of the substrate envelopes from 
observations, the protrusions of the functional group to some extent suggests that it is susceptible to the 
drug resistances, therefore, the mutation on the amino acid has greater influence on the binding affinity to 
the inhibitor than that of substrate. Therefore to minimize the region outside of the substrate envelope 
enhances the drug potentiation and overcomes drug resistances. (A.Schiffer, 2008). Based on these 
principles, drug optimization can be carried out by altering the functional group outside the substrate 
envelope, yet still keep the core structure to maintain its main tight binding to the protease. 
According to the previous study, both APV and DRV give relative steady affinity to the mutant virus 
strands, and also they fit better in the substrate envelops. In addition, most of the drugs approved by FDA 
have a three dimensional geometry that covers the hypothesized substrate pocket from P3’ position to P3. 
Among the nine drug inhibitors, DRV and APV have the smallest size, ranging from P2’ to P2. The size 
of the compound gives them an advantage to fit into the substrate envelope easily. However, also because 
of their smaller sizes, they have less functional groups which can interact with the enzyme. This does not 
mean the size will influence inhibitor binding affinity. According to the theory of substrate envelope, not 
all the active sites need to interact with substrate. In fact, only a small amount of the active sites are used. 
Therefore, our small-size protease inhibitors actually have advantages of binding to the protease and 
avoiding drug resistances. Therefore, APV and DRV were chosen as the model for drug design.  
According to the principle of the substrate envelope, the drug optimization can be processed on the 
current models of APV and DRV. Looking closer at the APV and DRV structure, one of the sulfonamide 
oxygens protrudes out of the substrate envelope; our goal is to convert the protruding functional group to 
avoid drug resistances, yet to conserve the original core model kinetics interaction ability. The synthetic 
chemistry is based on the medicinal chemistry principles to generate a non-peptidic but peptide-like drug. 
It is hypothesized that the modified isostere-based peptidomimetic drug should have relative improvement 
against drug resistance and also keep the same inhibition ability to wild type.  
 Figure 8. the rationale of new drug design principle. Panel A. Overlapping of van der Waals volume of four or more substrate 
amino acid chain to generate substrate envelope. Panel B. Overlapping of van der Waals volume of eight or more substrate amino 
acid chains to generate substrate envelope. Panel C shows the superimposed substrate envelops and inhibitor envelop. The 
volume that out of substrate envelope and inhibitor envelope overlapped region is usually susceptible to the drug resistances 
when the labeled mutant residue happens on protease. (Schiffer) 
 Figure 9.  Illustrations of the APV and DRV in the 2D and 3D structures. The part highlighted with red color is the core isostere 
scaffold of the peptidemic drug. The red color are the mutation sites which that APV and DRV protrudes outside of the substrate 
envelope and the sites highlight with blue are those on the border line of substrate envelops. The color indication came from 
figure8. And in this case, TMC114 is DRV. 
 
 
 
 
 
 
The proposed final core model and synthesis of inhibitor drug 
 
 
 
 
 
Materials and Methods 
Synthesis of Dipeptide Isostere Cores and Designed Protease Inhibitors 
Synthesis of (R)-Ethyl 5-((S)-1-(tert-butoxycarbonylamino)-2-phenylethyl)-2-
oxotetrahydrofuran-3-carboxylate 
 
 
 Epoxides 1 (20g, 75.96mmol) and liquid diethylmalonate(14.6g, 87.36mmol)  dissolved in 99.9 %ethanol 
(150ml). The reaction mixture was stirred at 0 
o
C, and then NaOEt (6.2g, 91.15mmol) was added drop-
wisely in 30 min. The resulting mixture was stirred for 15min, then was warmed to room temperature and 
was continuing to stir for 5 h. The resulting mixture showed no starting material was detected by TLC 
(EtOAc/hexanes 1:3). Reaction was quenched by adding EtOAc at 5 
o
C. The aqueous layer was extracted 
with EtOAc (2×250ml).Then extracted fractions were combined and washed with saturated NaCl, 
5%NaHCO3 (2×400ml).The washed extract was dried ( Na2SO4), filtered, and evaporated. The residue 
was dissolved in MTBE (100mL) at 60
o
C, and heptane (100mL) was slowly added to have the same ratio 
as MTBE. The solution was cool over night at 4
o
C. White crystal 2 (16.2g, 79%) was collected, filtered 
and air dried.  
 
 
 
 
 
Synthesis of tert-Butyl (S)-1-((R)-5-oxotetrahydrofuran-2-yl)-2-
phenylethylcarbamate 
 
The ester 2 solid (5.41g, 14.34 mmol) was dissolved in 1, 2-dimethoxyethane (DME) (50mL) at room 
temperature, and then was slowly added with a solution of LiOH•H2O (3.006g, 71.68mmol) in H2O (50 
mL) over 10 min. The resulting mixture was stirred at room temperature till no starting material was 
detected by TLC (EtOAc/hexanes 1:3). After 6hrs, the reaction mixture was cooled to 0 °C and 10% of 
citric acid was added to bring pH to 6. The resulting mixture was stirred at room temperature for 30 min 
and then partially evaporated under reduced pressure (keeping the bath temperature at 25 °C to remove 
most of the DME). The pH value of the solution was adjusted to pH ~3 using 2 N HCl (20 mL). The 
residual aqueous portion was repeatedly extracted with EtOAc (4 × 150 mL), the combined EtOAc 
fraction was washed with saturated aqueous NaCl solution (75 mL), dried (Na2SO4), and evaporated 
under reduced pressure to provide the acid 3 as a foamy solid (4.0g, 80%). The resulting mixture showed 
no starting material was detected by TLC (EtOAc/hexanes 1:2) A solution of the crude acid 3 in toluene 
(50 mL) was heated at 120 °C overnight, cooled to room temperature, and evaporated to dryness. The 
colorless gummy residue was purified by flash chromatography, eluting with 30% EtOAc in hexanes, to 
provide the lactone 4 (2.51 g, 57.3%) as a white powdered solid. 1H NMR (400MHz, CDCl3)δ 7.34-7.29 
(m, 2H) 7.27-7.26 (m,1H) 7.25-7.19 (m,2H) 4.45-4.35 (m,2H)(brd) 4.0-3.90(m,1H) 3.05-2.95 (q, J=4.4Hz, 
1H) 2.65-2.47 (m,2H) 2.30-2.20 (m,1H) 2.17-2.04(m,1H) 1.55-1.5(m,9H)  
 
 
Synthesis of tert-Butyl (S)-1-((2R,4R)-4-(1-hydroxy-3-methylbutyl)-5-
oxotetrahydrofuran-2-yl)-2 phenylethylcarbamate 
  
 
The lactone 4 (1g, 3.27mmol) was dried on desiccator over night before the proceeding of the reaction.  A 
solution of n-butyl lithium (1.6M) (4.51mL, 7.22mmol) was slowly added into a solution of 
diisopropylamine(1.02 mL, 7.312 mmol)  in anhydrous THF (15ml) under Nitrogen atmosphere at -78
o
C. 
After 30 min, lactone 5 (1g, 3.27mmol) dissolved in 4mL THF drop-wisely to the mixture over a period 
of 15 min. After 40 min, 3-dimethyl aldehyde (0.80mL, 7.1 mmol) was added drop-wisely to the mixture. 
The reaction mixture was stirring under same time temperature for 80 minutes, and then was quenched by 
NH4Cl. (1M) (3mL, mmol).Raise to room temperature, the organic layer of the product was extracted by 
EtOAc (2×80mL). The product washed with 5%NaHCl (50mL), 25%NaCl (80mL) and then was dried 
(Na2SO4), filtered, and vacuumed to yield a crude yellow colored viscous oily product 5 (1.57g) was 
generated. The yellow and foaming product showed only a little starting material was detected by TLC 
(EtOAc/hexanes 1:2) TLC with EtOAc-hexanes (1: 3). 
 
 
 
 
 
 
Synthesis of tert-Butyl (S)-1-((2R,4R)-4-isopentyl-5-oxotetrahydrofuran-2-yl)-
2-phenylethylcarbamate 
 
Acetic anhydride (1.5mL) and triethylamine N (CH2CH3)3 (1.5mL) were added to the dried crude product 
of 5.  The reaction mixture was stirring in oil bath at 120
o
C for 2h and was then cooled to room 
temperature (RT). The organic layer was extracted by ethyl ether (2×40mL). The product was washed 
with 10% citric acid, saturated NaHCO3 and brine, dried (MgSO4), filtered and vacuumed to result in 
product 6(1.45g.) The crude product 6 was dissolved in the mixture of ethyl acetate and methanol (25mL) 
(EtOAc/MeOH4:1) Pt /C catalyst (100mg, 10%) was added to accelerate the reaction. Under hydrogen 
atmosphere and increased pressure, the reaction mixture was stirring overnight at RT. The product was 
filtered through celite. The organic layer was extracted by EtOAc, (2×80mL) evaporated under reduced 
pressure to yield a white crystal solid, the resulting mixture showed only slightly of starting material was 
detected by TLC. Then the residue was purified by flash chromatography on silica gel, eluting with a 
mixture of EtOAc-hexanes (200mL of 15% of EtOAc, 300mL of 20% of EtOAc, 300mL of 25% of 
EtOAc, 100mL of 30% of EtOAc) The purified fractions were collected and high vacuumed to result in 
transparent clear oily product 7(5.08g, 82.75%) 
1
H NMR (400MHz, CDCl3)δ 7.33-7.23 (m, 2H) 7.26-7.23 
(m,1H) 7.22-7.19 (m,2H) 4.45 (m,1H)(brd) 4.27 (brs,1H) 4.94 (brs,1H) 3.02 (dd, J=14.0,4.4Hz) 2.91-2.86 
(m,1H) 2.60-2.51(m,1H) 2.43-2.36 (m,1H) 1.97-1.88 (m,1H) 1.70-1.71 (q, J=11.6Hz, 1H) 1.57-1.50 (m, 
1H).1.46-1.32 (m, 1H) 1.37(s,9H) 1.29-1.16 (m,2H) 0.89 (d,J=6.8Hz, 3H) 0.88 (d,J=6.8Hz,3H). 
Synthesis of tert-Butyl (2R,3R,5R)-3-hydroxy-5-(methoxy(methyl)carbamoyl)-
8-methyl-1-phenylnonan-2-ylcarbamate 
  
White and flaky powder of N, O-dimethylhydroxdylamide hydrochloride (0.324g)was added to 
dichloromethane (99.9%, 14mL) in a 50mL round bottle flask. The reaction was kept in nitrogen 
atmosphere and allowed to cool the temperature to 0
o
C. Me2AlCl (3.3ml, 1M) was added drop-wisely to 
flask over 10 minutes period. The reaction mixture was stirring for 1h, then temperature was raised to RT, 
and starting material 7(0.25g, 0.667mmol) dissolved in CH2Cl2 (7mL).Reaction was maintained overnight, 
then was quenched by adding phosphate buffer (pH=8, 10mL) very slowly to avoid sudden pressure 
increase. After product was stirring for 10min, diluted with chloroform CHCl3, filtered through celite, and 
then the aqueous layer was extracted by EtOAc (2×100ml). The organic layer was then washed with brine, 
dried (MgSO4), filtered, and high vacuumed to result in crude yellow solid product 8 (0.26g, 89%.) The 
resulting mixture showed that no starting material was detected by TLC (EtOAc/hexanes 6:4) 
 
 
 
 
 
 
Synthesis of tert-butyl (2S,3R,5R)-3-(tert-butyldimethylsilyloxy)-5-
(methoxy(methyl)carbamoyl)-8-methyl-henylnonan-2-ylcarbamate 
 
Crude product 8( 5.29g, 12.036mmol) has been high vacuumed for 1h, and then it was dissolved in DMF 
(100mL), and tert-butyldimethyl chlorosilane (TBSCl) (18.35g, 120.36mmol) and imidazole(8.194g, 
20.36mmol) were added into the 250mL round bottom flask, the reaction mixture was stirring for 48 hrs 
at room temperature, then it was quenched by methanol(50mL). The product was extracted by EtOAc 
(2*100mL). And vacuum until completed dry. The resulting crude product showed was some starting 
material was detected by TLC (EtOAc/hexanes1:2). Then the residue was purified by flash 
chromatography on silica gel, eluting with a mixture of EtOAc-hexanes (15% of EtOAc (1000mL), 20% 
of EtOAc (1000mL).100% ETOAc(300mL) to elute all the starting material 9.  The purified product was 
collected and was high vacuum for 2h, then placed in desiccators for 24 hrs before run H-NMR. The 
resulted product appears transparent oily viscous liquid 10 (4.09g, 61.17%).  
 
 
 
 
 
 
 
Synthesis of   tert-butyl (2S,3R,5R)-5-benzoyl-3-hydroxy-8-methyl-1-
phenylnonan-2-ylcarbamate 
  
Starting material 9, Boc Weinreb amide, (0.200g 0.360mmol) was dissolved into THF (2mL) under 
nitrogen atmosphere. Cool the solution to -15
o
C and i-PrMgCl/THF (0.2mL, 0.360mmol) was added drop 
wisely. After the reaction mixture was cooled to -15
o
C again, ph-MgCl/THF (2.0M, 0.25mL) was added 
slowly and the mixture was continuing stirring for1h. Remove the bucket of ice and salt bath, and reaction 
mixture was kept for 2hrs. HCl (1N, 2mL) was slowly added at temperature (< 20
o
C) to quench the 
reaction. The reaction mixture was extracted by EtOAc(2×40mL), then was washed with brine, dried 
(MgSO4) , filtered and high vacuumed, then the residue was purified by flash chromatography on silica 
gel, eluting with a mixture of EtOAc-hexanes (600mL of 20% of the EtOAC, and 100mL of 30% of 
EtoAC) The fraction with purified product 10 was collected. (60mg, 52.044 %) 
1
H NMR (400MHz, 
CDCl3)δ 7.49-7.45 (m, 2H) 7.32-7.24 (m,4H) 7.23-7.16 (m, 2H) 7.15-7.11 (m, 1H) 4.54-4.48(m, 1H) 
3.88-3.76 (S,1H) 3.75-3.64 (m,1H) 3.2-3.1 (s, 1H) 2.6-2.8(m,2H) 1.6-1.5 (m,4H) 1.44-1.16 (m,9H) 1.15-
0.95 (m, 1H) 0.94-0.8(m,3H) 0.68-0.74(m,3H). 
 
 
Future steps to complete the inhibitor design I 
 
Future steps to complete (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl 
(2S,3R,5R)-5-benzoyl-3-hydroxy-8-methyl-1-phenylnonan-2-ylcarbamate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Synthesis of tert-Butyl (2R,3R,5R)-5-(3-chlorobenzylcarbamoyl)-3-hydroxy-8-
methyl-1-phenylnonan-2-ylcarbamate  
 
White and flaky powder of 3-chlorobenzylamide (1.3mL, 10.65mmol) was added to dichloromethane 
(99.9%, 30mL) in a 100mL round bottle flask. The reaction was kept in nitrogen atmosphere and allowed 
to cool the temperature to 0
o
C. Me2AlCl (1M, 10.65ml, 10.65mmol) was added drop-wisely to flask over 
10 minutes period. The reaction mixture was stirring for 1h, then temperature was raised to RT, and 
starting material 7(0.800 g, 2.13mmol) dissolved in CH2Cl2 (15mL).Reaction was maintained overnight, 
then was quenched by adding phosphate buffer (pH=8, 30mL) very slowly to avoid sudden pressure 
increase. After product was stirring for 10min, diluted with chloroform CHCl3, filtered through celite, and 
then the aqueous layer was extracted by EtOAc (2×200mL). The organic layer was then washed with 
brine, dried (MgSO4), filtered, and high vacuumed to result in crude yellow solid product 11(0.25g).The 
resulting mixture showed that no starting material was detected by TLC (EtOAc/hexanes 6:4) 
 
 
 
 
 
 
 
 
Synthesis of (S)-Tetrahydrofuran-3-yl (2S, 3R, 5R)-5-(3-
chlorobenzylcarbamoyl)-3-hydroxy-8-methyl-1-phenylnonan-2-ylcarbamate  
 
To a solution of the tert-butyl (2R,3R,5R)-5-(3-chlorobenzylcarbamoyl)-3-hydroxy-8-methyl-1-
phenylnonan-2-ylcarbamate 11(0.25 g, 0.48 mmol) in CH2Cl2 (6 mL) was added trifluoroacetic acid (3 
mL) and the resulting mixture was stirred at room temperature for 1 h. The reaction mixture was 
concentrated under reduced pressure; the residue was dissolved in toluene (10 mL) and evaporated at 
reduced pressure to dryness. The resulting de-protected amine was dissolved in dry CH3CN (5 mL) and 
the solution was cooled 0 °C. DIPEA (0.32 mL, 1.94 mmol) was added and after 15 min solid THF-
carbonate (0.122 g, 0.48 mmol) was added in one portion; the resulting reaction mixture was stirred at 
0 °C for 15 min, allowed to warm to room temperature, and stirred until reaction was complete 
(monitored by TLC). The reaction mixture was evaporated and the residue was purified by flash 
chromatography on silica gel, eluting with a gradient mixture of EtOAc-hexanes, to afford the target 
compound 12 as a white solid. 1H NMR (400MHz, CDCl3)δ 6.15-6.05 (m, 1H) 5.12-5.05 (m,1H)(brd)  
4.93-4.85 (d, J=8.8Hz,1H) 4.55-4.45 (q, J=6.4Hz, 15.2Hz, 1H) 2.94-2.86 (m,2H) 2.81-2.70 (m,1H) 2.30-
2.21(m,1H) 1.99-1.82 (m,2H) 1.70-1.40(m,5H) 1.20-1.05 (m,2H) 0.94-0.90(m,2H) 0.81-0.84 (d, J=64Hz, 
6H)  
 
 
 
 
HIV-1 Protease inhibitor enzymatic inhibition constant evaluation-
Fluorescence Resonance Energy Transfer Assay (FRET)  
The in-vitro biological activities of the synthesized HIV protease inhibitors were measured by 
fluorescence Resonance Energy Transfer (FRET) Assays. HIV protease substrate-1 (H-2930) was 
purchased from molecular Probes. (Eugene, OR, USA). Substrate stock concentration of 500 uM were 
used for all assays. The high quality anhydrous dimethyl sulfoxide (DMSO) was used to dilute the 
synthetic peptide substrate (Arg-Glu(EDANS)-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-Lys(dabcyl) –Arg). The 
substrate has an energy transfer donor (EDANS) and an acceptor (DABCYL) at each terminus of the 
substrate peptide chain. Its molecular weight is 2016 Dalton and it has excitation maximum wavelength at 
340 nm and emission maximum wavelength at 490 nm (after cleavage). Fluorescence measurements were 
conducted on a fluorescence spectrophotometer (Photon Technology International, Brimingham, NJ, USA) 
at 25 °C.  HIV protease assay buffer (0.1M sodium acetate, 1.0 M sodium chloride, 1.0 nM 
ethylenediaminetetram acetic acid (EDTA), 1.0 mM dithiothreitol (DTT) 2%, dimethylsulfoxide (DMSO), 
1mg/mL bovine Serum albumin (BSA) at pH4.7) was used to prepare substrate and make a concentration 
of 1uM. Each protease inhibitor was tested against wild-type and mutant HIV-1 protease. The wild-type 
protease (Q7K) was purified by PD-10 column (Amersham Biosciences, Uppsala, Sweden), elution buffer 
was sodium acetate (20 mm, pH 5). The mutant HIV proteases were selected from the Stanford HIV-1 
Drug Resistance Database (Website ref.), and the protease mutations in mutant protease 1 (M1)are L101, 
G48V, I54V, L63P  ; L101, L63P, A71V, G73S, 184V, L90M in mutant protease 2( M2), and I50V and 
A71V in mutant protease 3 (M3).  For comparison purposes, the APV was studied against the WT and 
mutant proteases. The concentration of all proteases was 50 nM, measured by Ultra-Vis spectrometer at 
280 nm. All of the inhibitors were diluted with DMSO to reach the desired concentrations. Inhibitor 
dissociation constant (Ki) were determined by nonlinear regression fitting (grafit5, Erithacus Software 
Surrey, UK). The initial velocity of each reaction at different concentrations was determined by linear 
regression of the curve at initial stage.   The plots of initial velocity verses concentration of inhibitors 
were constructed, and the Ki was derived using Morrison equation.  
Results:  
To test on our hypothesis of drug design, we first attempted to synthesize compound 1-A, and later on we 
synthesized the alternative design 2-A. After purifying the new compound 12, we evaluated its enzymatic 
characteristics. The results demonstrated that our hypothesis of designing a keto-hydroxyethylene core is 
valid, and there are many more tests that can be conducted in the future to make a further confirmation. 
Florescent resonance energy transfer assays were conducted to determine the Ki value of the inhibitor and 
to measure its binding affinity to a wild type or mutant proteases (M1-M3).  Meanwhile, the relevant 
eight new protease inhibitors provided by collaborators were also tested by FRET assay to complement 
the analysis. Those eight compounds are composed of an APV benzenesulfonamide core, incorporating a 
variety of functional groups at position P2, P1’ and P2’. They were also evaluated for biological activities 
against WT and M1-M3 HIV-1 proteases. The lists of Ki values are presented in table 4. All of the Ki 
values were determined from a triplicate assay experiment performed on each compound  to maintain 
statistical significance of the results.  
Evaluation of compounds 1A  
Protease inhibitor with keto-hydroxyethylene core, named as 1A, was still in the process of synthesis. 
Due to the limited amount of time and the difficulty in eliminating anonymous impurities from the 
reaction, the test of this designed compound was not able to be conducted at this stage.  The main 
challenging phase is to separate the unknown side products which have very similar chemical properties 
as the desired product. It creates difficulty during flash chromatography. The reaction scheme has been 
modified by adding protection groups, such as N-methoxy-N-methyl and tert-butyl-dimethyl silanyloxy. 
It is used to reduce the effect of undesirable proton-based reactions during the experiment. However, 
results from TLC and NMR both suggest that synthesis had encountered impurity issues. An improved 
methodology needs to be developed in order to optimize the reaction scheme. After the designed protease 
inhibitor is synthesized, biological activities of the protease inhibitor 1-A will be tested in the future.  
Evaluation of compound 12 with new keto-hydroxyethylene core.  
Alternatively, the new protease inhibitors, compound 12, also have the keto-hydroxyethylene core. It has 
been synthesized and purified through flash chromatography and confirmed by NMR. It is estimated that 
the sample of compound 12 used for the FRET assay has a purity of 90%. FRET assay was conducted by 
taking eleven data points with inhibitor concentration ranges from 12.5nM, 37.5nM, 75nM, 100nM, 
125nM, 150nM, 187.5nM, 250nM, 375nM, 500nM, to 625nM. The generated data are processed through 
grafit5 software. Based on Michaelis-Menten Kinetics theory, the assumption for the Michaelis-Menten 
equation to establish is only when the concentration of the substrate is significant greater than that of 
enzyme inhibitors; therefore, each inhibitor sample was tested on the condition with 1uM substrate.  
Every reading of the enzyme reaction was measured in real time in five minutes and monitored by 
fluorescent spectrometer. We know that the protease cleavage is time-dependent process that the amount 
of substrate cleaved is linearly proportional to the intensity of fluorescence. If inhibitor did not block 
protease from binding the substrate, then protease will cleave the substrates between Tyr-Pro bonds which 
is at the middle of the peptide chain. This triggers the originally quenched donor EDANS to float freely, 
regain its full fluorescence quantum yield and concomitant free-floating receptor DABCYL-linked 
peptide. The graph of intensity verse time is equivalent to the amount of substrate cleaved verse time.  
And only at the initial stage of the enzyme kinetic model, relationship between products and time is linear, 
and it passes the initial stage, the speed will slow down and eventually reach the Plato. Therefore, we take 
all the value of initial velocity construct a graph against each concentration of the inhibitor, shown in 
figure11,12,13. (They are triplicates.) And grafit5 software applies Morrison equation to calculate Ki. The 
equation is shown in figure10. 
It can be concluded that our inhibitor compound 12 displays a fair inhibitory ability against WT (Q7K) 
HIV-1 protease (Ki = 21.33+2.97nM). Compare to control drug (Amprenavir), which is a potent HIV-1 
protease inhibitor (Ki = 0.1 nM), the Ki of the new synthesized protease inhibitor compound 12 is higher 
which means our compound loses certain binding affinity in order to compromise to against drug 
resistances. However, this is only one of the structures.  If the side chain of P1’ and P2’can be 
manipulated in the future with different combinations, and the P1’ increases in hydrophobicity, which can 
have a stronger interactions with the protease and increase the affinity. Therefore, at this stage, it cannot 
make a definite conclusion yet.  
 
Figure 10.  The equation on the left is Morrison equation. It obeys the assumption. f= faction of active enzyme, E=50nM. 
S=1uM. And the Non-linear regression is fitting for Ki, C and f. 
 
 
 
 
 
 
 
 
 
Figure 11. FRET test trial 1 of compound 12.  
  
 Figure 12. FRET test trial 2 of compound 12.  
 
Figure 13. FRET test trial 3 of compound 12.  
Evaluation of the eight relevant APV analogues by FRET assays 
Eight HIV protease inhibitors (APV analogues), synthesized by collaborator, Dr. Tariq Rena’s research 
group from Burnham Institute, were also tested through FRET assay.  The test for enzymatic activities of 
eight compounds follows the same method as that for compound 12. The result of protease inhibitor 
against WT and M1-M3 are listed in table5. According to articles, APV has an increase of Ki to 0.33nM 
toMutants3 (I50V). (Clavel, 2004) It has been reported that APV also encountered drug resistance in the 
clinical tests. Therefore, the main focus of those tests is to see if the new designed drug overcomes the 
drug resistance issue on M3, and if they still remain the excellent potency to other mutations (M1-M2).  
Overall, the results show that compound MPK 69, MPK73, MKP 75, MPK97, MPK101 all exhibit strong 
affinity to M1, M2 and M3. However they all lose certain degree of affinity to mutant proteases than to 
the WT. The best compounds MPK69 among all eight even have better efficacy than control APV and 
DRV. It displays incredibly strong affinity to the WT protease and M3. Its Ki is 1pM for wild type and 
57pM for mutant3. According to the literature reports, the Ki of APV to mutantM1, M2, and M3 are 
0.15nM, 0.21 and 0.34nM. Other than compound MPK69, MPK 73, 101 also have high binding affinity 
to the WT protease. Comparing to the activity of APV against M3, they even have better strengths. 
(MPK101, Ki=0.265, MPK73, Ki= 0.297).  On the other hands, there is some non-potent drug candidate 
were tested out as well. MPK 52 actually has 100 fold decreases in inhibitory ability against mutant M1, 
M2, andM3 than that to WT. This result suggests that compound MPK52 might be susceptible to drug 
resistances. MPK 39 shows the worst biological activity of all those eight compounds.  The Ki values of 
MPK39 to M1-M3 are 100-1000 fold higher than that of MPK69.  
Do the determined Ki values of those compounds suggest confirm with our drug design rationale? First 
all of, drug candidate MPK52, 69,101,75,73,98,97 all shows better or equal inhibitory abilities as their 
backbone model APV. Secondly, inhibitor MPK73 and 97 maintains the potent affinity to all those three 
mutant proteases. Thirdly, inhibitor MPK 69, 101, 73 and 97 conserve their capability to overcome drug 
resistance caused by M3, the one which APV had a significant issue of drug resistance. The excellent 
behavior of those compounds indicates they are potential drug candidates for the future studies. On the 
other hand, even though MPK98 exhibits powerful interaction with WT, M2 and M3, there is a 100 fold 
decreases of enzymatic activity to M1 (G48V, V82V). This suggests that it might not be an ideal 
candidate for future study since it gains the ability to overcome drug resistance compared to APV, but at 
the same time, it loses its ability to overcome to other types of mutant that APV could against.   
 Compare the eight APV analogs our synthesized compound 12, they all exhibits stronger enzymatic 
kinetic characteristics than compound12. (Ki=21.33nM). However, the conclusion that keto-
hydroxyethylene design did not confirm with hypothesis based on presented result should not be made as 
this stage. A more comprehensive analysis will be illustrated in the discussion section. The reason that the 
eight compounds exhibits effective enzymatic activity is might be due to the reason that they have higher 
hydrophobicity at P1’ position, which is considered as suitable for increasing the nonpolar interaction 
with protease at activity sites.  
Table 3. Mutant amino acid residue list for M1-M3 HIV protease. 
Mutant Mutation sites  
Mutant1 (2) L101, G48V, I54V, L63P, V82A 
Mutant2 (4)  L101, l63P, A71V, G73S, 184L , L90M 
Mutant3 (5) 150V, A71V  
 
Table 4. The result of Ki of all those eight relevant HIV protease inhibitors against to WT and mutants protease. 
Inhibitor  Structure  Molecular 
weight  
Wildtype 
protease  
Mutant 1 
G48V, V82V 
Mutant 2 
184V, L90M 
Mutant 3 
150V 
SBMRI-
MKP 
MPK39 
 
591.74 11.39±0.62 180.0.0±16.0 45.92±4.28 119.6±13.3 
MPK52 
 
591.74 0.590±0.017 11.72±3.54 12.04±0.71 24.19±6.94 
MPK69 
 
645.62 0.001±0.001 1.345±0.312 1.074±0.238 0.057±0.006 
MPK101 
 
645.62 0.096± 1.481±0.327 1.269±0.622 0.265±0.016 
MPK75 
 
564.69 0.406±0.005 2.801±0.335 1.665±0.532 1.7950.452 
MPK73 
 
564.69 0.018±0.006 0.302±0.145 0.373±0.140 0.297±0.059 
MPK98 
 
588.74 0.027±0.020 7.020±0.925 1.126±0.384 1.009±0.114 
MPK97 
 
 
588.74 0.027±0.021 0.299±0.235 0.341±0.197 0.377±0.100 
Discussion  
Structure-Activity relationship investigation  
The protease inhibitors compound12 exhibit a moderate enzymatic inhibitory constant. Comparing to 
control APV (Ki=0.1nM). (Madhavi N. L. Nalam, 2010) the keto-hydroxyethylene seems decreases 35 
fold in the affinity to protease. However, many explanations can interpret this phenomenon. First of all, 
according to the rationale, this keto-hydrooxyethylene core structure is designed to overcome drug 
resistance issues. As a result, the three dimensioned molecular structure fits into the hypothesized 
substrate envelope, it might loses some level of affinity to the protease at initial stage to be able to  locate 
within the overlapping consensus volume of the substrates. According to the article “evaluating the 
substrate envelope hypothesis” published in 2010 by Madhavi N.L. Nalam and Akbar Ali, the compounds 
with a  binding affinities ranging from 58nM to 0.8 pM, were considered as potent protease inhibitors and 
used for crystallographic analysis , therefore, it can be concluded that new core scaffold was tested 
aligned with the hypothesis.  
Secondly, the new core at this stage is only designed to build a potential scaffold, and inhibitor 
compound12 is only one of the many possibilities that could be built from this core. As we can observe 
that at p1’ position, isopropyl group of compound12 can be modified into a more nonpolar functional 
group such as n-butyl. to increase the hydrophobicity interaction at p1’ position with the hypothesized 
substrate envelope. In addition, the group on P2’, P1 and P2 also can be manipulated to make 
combinations of function groups. A compound library can be constructed and the best candidates can be 
screen from compound family. Therefore, from the chemical hydrophobicity interactions point of view, 
the synthesized new core and its inhibitor still fall into the right directions.  
Thirdly, our synthesized inhibitor is only one of the four possible stereoisomer, such as in the introduction 
section, we proposed idea of synthesis compound 1-A, 1-B, 1-C and 1-D.( they are stereo isomers). From 
previous studies, there are cases that changes in the chirality of one of the chiral center from 
peptidomimetic compound, its biological activity will be completely different. The differences in the 
three-dimensional orientations of the atom in the spaces will result different binding energy, binding 
distances and forces of interactions. In the future, our inhibitors isomers will be synthesized to test on 
their activities. Therefore, our designs are still have many potential to go further to the evolution of the 
new core development.  
Fourth, more in-depth structural and bonding energy analysis need be demonstrated in order to further 
analyze the potential of the new core and inhibitors. The van der Waals interactions between protease 
inhibitors and protease, the investigation on conservation and variation of hydrogen bonds, evaluation on 
how well the protease inhibitor fits into the substrate hypothesis by docking program and computations, 
the effects of plasticity of HIV-1 protease on binding ligands analysis should be conducted in the future to 
have a comprehensive understanding of the chemical and biological potency of the new inhibitor. 
Therefore, at this stage, the development of inhibitor compound 12 demonstrates its enzymatic 
effectiveness and potential to be the new influential scaffold for drug design. It might even optimize the 
APV model to a novel evolution.  
Inhibitor biochemical activities against WT HIV-1 protease  
The product compound 12 has a functional group of THF, a cyclic heterocyclic. It is a common functional 
group used in the biological system, since it resembles the side chain of the amino acid proline. The 
heteroatom of heterocyclic molecules can be oxygen, sulfur, or nitrogen. The ring structure generates 
hydrophobicity interactions with the protease, and the heteroatom usually forms hydrogen bonding 
interaction with protease. This functional group at P2 position is same as that for APV (Weight 505.6270). 
The location of phenyl functional group at P1 position displays strong hydrophobic interaction, and 
hydroxyl group forms hydrogen bonds with protease as well. At position P1’ isobutyl should be replaced 
by a more hydrophobic functional group. The 3-chlorobenzylcarbamoyl group still keeps the aromatic 
ring to conserve its intermolecular bonding. However we compared to compound 12 to APV: APV has an 
amine group at the same position which can generate more hydrogen bonding interactions with the 
protease. Those might provide an explanation for the reason that inhibitor 12 has higher Ki than the 
control APV.  But, chloride atom on compound 12 can be altered later in the future optimization 
procedure. And the two oxygen atoms from the benzenesulfonamide core of APV (Ki=0.100nM) and 
DRV (Ki=0.008nM) (Antiviral EC50 Values, 2007) generates hydrogen bonds with the flap residues that 
belongs to enzyme active sites. (Nalam, 2007) The sulfonamide group was converted into keto in our core 
based on our rationale. However, it seems the reduced number of oxygen atom also contribute to the 
temporary loss of intermolecular affinity. If a more numerically crystallization analysis can be conducted 
on our compound 12, then we can picture how well our inhibitor binds to the active sites to both the WT 
and mutants. Then we would see the crystallization graph to analyze the bonding interactions at atomatic  
level. The crystallization analysis of DRV might provide some clue for us to understand our compound 
12. , shown in figure 14 and 15.  First of all, it is needed to clarify that only structure difference from 
APV to DRV is located at P2 sites. The THF group of APV is replaced by a fused bicyclic 
tetrahydrofuran moiety. This is due to the reason that THF help to create more hydrogen bonds with 
active sites Asp29 and Asp30 NH (DominiqueL.N.G., 2005). It is predicted that our inhibitor modified 
based on APV and DRV, would have the similar chemistry interactions with wild type protease. THF of 
our inhibitor would interact with the Asp29 and Asp30 as well. And the amide group on p2 position from 
hydrogen bonds with water molecule, and the water molecule with interacts with the active sites at  
Isoleucine 50`. And the hydroxyl group forms four hydrogen bonds with the Asp25 and Asp25’. The keto 
group will interact with I50 as However, as you see on the right of figure, the primary amine interacts 
with water molecules and the Asp30’ and Asp29’ of the APV and DRV, did not happen in our inhibitor 
since we have chorine rather than amine.  
The eight relevant compounds were also tested by FRET, since they are designed based on the APV and 
DRV models as well.  The different between this series to our inhibitor is that they have different 
functional group on position P2 and P2’ and different core.  The most potent MPK69 have an extensive 
chain at P2 position which increases the opportunity to generate more intermolecular interactions with the 
active sites Asp-Thr-Gly triad from 25( 25’)-26(26’)-27(27’).  
Inhibitor activities against mutants M1-M3  
Since our protease inhibitor compound 12 shows moderate inhibitory ability against to wild type, in the 
future, inhibitor against mutants M1-M3 can be tested as well. According to the previous scientific studies, 
the inhibitory ability of compound against mutant virus might decrease. The major residues mutant causes 
drug resistances on APV are I50 and I84, which interacts with the oxygen of benzenesulfonamide group 
of APV.  The drug resistances caused by those two residues should not happen on our compound 
12.However, further demonstration on crystallization analysis need to be conducted to supplement this 
result. The other drug resistances residue mutation are reported as I50’ and V82’. This situation might still 
happen on our inhibitor since we keep the same phenol ring at P1 position. The test result on M3 
demonstrated that some of the compounds based on APV and DRV model have overcome the drug 
resistances issue even though they still keep the sulfonamide group in the core. This might suggest that if 
other functional group at P2, P1’ and P2’ position can gain interactions with the mutant protease; it can 
balance the loss of affinity on the oxygen atom on the sulfonamide group in the core. However, compared 
to control APV and DRV, some of those compound loss affinity to M1 and M2 even though they are 
potent to M3, such as compound MPK 101. This demonstrated that even through some designed 
compound targeting at resolve drug resistance issue on specific mutated residues; it still does not 
predicted whether the alternation of the structure will keep the same potency to other mutants.  
 Figure 14.  DRV crystal structure interaction with HIV wild type protease 
. 
 
Figure 11. structure and binding mode of the DRV 
  
Conclusion  
In summary, we have discovered novel HIV protease inhibitor designed based on substrate envelops. The 
HIV inhibitor biological activities have been tested by FRET assay; all those analyses have demonstrated 
that our protease inhibitor is still considered as a potent drug inhibitor at initial stage. The protease 
inhibitor with novel keto-hydroxyethylene core provide successful scaffold for the future series of drug 
inhibitor development. It has opened a new door to develop HIV drugs with higher efficacy against both 
the wild type and mutants. The unlimited potential will provide possible drug candidate in the future 
which behaviors greatly in pharmaceutical kinetics and dynamics. The investigation of the new core 
supports the idea of drug design based on the substrate envelope It complements other method to 
approach HIV drug design, such as based on the original natural product model, and provide broad 
spectrum of perspective for the development of HIV drug against drug resistances. HIV protease inhibitor 
will become the developed model for other viral protease inhibitor. It brightens the path for the scientists 
to explore on protease inhibitor design, for instance the treatment to HCV.  It implication certainly cannot 
be underestimate.  
In the future, the isomers of the compound 12 could be synthesized and the first attempted compound 1-A 
can be developed, and a series of compound based on keto-hydroxyethylene core library can be 
constructed. FRET assay will be used to test on those drugs against wild type HIV protease and mutant 
M1-M3 or even more types of mutants. Crystal structure and molecular model can be investigated and 
bioavailability and antiviral activities of these inhibitors also can be tested both in-vitro and in-vivo. 
 
 
 
 Figure 16. Wild type HIV-1 protease complexes with APV 
 Figure 17. HIV-1 protease with mutation sites (L10I, G48V, I54V, L63P, and V82A) complexes with APV.  
 Figure 18..HIV-1 protease with mutation site (L10I, I63P, A71V, G73S, I84V and L90M) complexes with APV 
 Figure19. HIV-1 protease with mutation site (I50V, A71V) complex with APV. 
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Appendix ( Ki determination for all those eight relevant compounds) 



 





   
 



           
